IBO

Insider Trades

Name	Value	Action	Price	Current Price
Macko Todd DChief Financial Officer $24k43.4k shares SellMar 27, 2026 $0.5615 --
Macko Todd DChief Financial Officer $9611.6k shares SellMar 25, 2026 $0.6008 --
Grady JasonDirector $33k50k shares SellMar 23, 2026 $0.6501 --
Dss, Inc.10 Percent Owner $25k45.4k shares SellMay 27, 2025 $0.5403 --
Dss, Inc.10 Percent Owner $25k45.4k shares SellMay 27, 2025 $0.5403 --
Dss, Inc.10 Percent Owner $63k115.6k shares SellMay 22, 2025 $0.5491 --

News

businesswire.comImpact Biomedical Investor News: Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBObusinesswire.comApr 12

businesswire.comRosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBObusinesswire.comApr 11

globenewswire.comImpact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plansglobenewswire.comApr 3

Trade IBO

About Impact BioMedical Inc.

Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.

CEO: Frank D. Heuszel
IPO Date: Sep 16, 2024

Market Data

Open: $0.56
High: $0.5925
Low: $0.56
Volume: 116.2K
52W High: $1.95
52W Low: $0.362

Valuation

Market Cap: $7.1M
Enterprise Value: $7.1M

Financials

Free Cash Flow: $-1.9M
Revenue: $32k
Net Income: $-12M
Cash: $3.0k
Debt: $0

Events

EarningsMay 12

actual -0.02